<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="45">
  <stage>Registered</stage>
  <submitdate>19/07/2005</submitdate>
  <approvaldate>19/07/2005</approvaldate>
  <actrnumber>ACTRN12605000028606</actrnumber>
  <trial_identification>
    <studytitle>Tenofovir versus Adefovir for the treatment of HBeAg positive chronic hepatitis B</studytitle>
    <scientifictitle>A randomised, phase III, double blind study to evaluate the efficacy and safety of tenofovir DF versus adefovir dipivoxil in the treatment of HBeAg positive chronic hepatitis B to suppress viral replication, amend the course of the disease and decrease morbidity.</scientifictitle>
    <utrn />
    <trialacronym>GS-US-174-0103</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>HBeAg  positive chronic hepatitis B</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To compare the efficacy of tenofovir DF 300 mg versus adefovir dipivoxil 10mg over 48 weeks of treatment</interventions>
    <comparator />
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary efficacy parameter is the proportion of patients treated with tenofovir DF 300mg QD versus adefovir dipivoxil 10 mg QD with a complete response.  A complete response is defined as serum HBV DNA levels below 400 copies/mL and histologic improvement defined as at least a 2 point reduction in the Knodell necroinflammatory score without worsening in the Knodell fibrosis score.</outcome>
      <timepoint>At the end of the 48 week treatment period.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To compare the safety and tolerability of tenofovir DF 300 mg QD versus adefovir dipivoxil 10mg QD.</outcome>
      <timepoint>Over the 48 week treatment period.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the incidence of drug-resistant mutations between treatment arms and to compare the virological, serological, biochemical and histologic response of tenofovir DF 300mg QD versus adefovir dipivoxil 10mg QD for the treatment of HBeAg positive chronic hepatitis B</outcome>
      <timepoint>Over 48 weeks of treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult patients (18-69 years of age) with HBeAg positive chronic hepatitis B (HBsAg positive for more than 6 months) with serum HBV DNA &gt;10 to the 6 copies /mL, ALT levels &gt;2 x ULN and less than or equal to 10x ULN and a Knodell necroinflammatory score of greater than or equal to 3 and a Knodell fibrosis score &lt; 4. However, up to 96 patients with cirrhosis, i.e. knodell fibrosis score equal to 4, will be eligible for enrollment. Patients who have not had a bopisy within 6 months at baseline must agree to undergo a liver biopsy prior to randomisation. No evidence of hepatocellular carcinoma (HCC) ie. fetoptotein 50 ng/mL at screening. Patients are wligible if they are treatment naive, ie less than 12 weeks of prior nucleoside or nucleotide (adefovir, dipivoxil or tenofovir DF) treatment. Any previous treatment with nucleosides and nucleotides (eg up to 12 weeks) and interferon (pegylated or not) must have ended at least 6 months prior to the pre-treatment biopsy. </inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype />
    <inclusivemaxage />
    <inclusivemaxagetype />
    <inclusivegender />
    <healthyvolunteer />
    <exclusivecriteria> Patients must be without HIV, HCV and HDV infection. Pregnant and breast feeding women will be excluded from the study and patients with decompensated liver disease or a history of decompensated liver disease (ascites, jaundice, encephalopathy or variceal haemorrhage) will be excluded from the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A centraloised randomisation procedure will be used whereby numbered bottles will be assigned to patients via an interactive voice response system (IVRS) according to the randomisation code</concealment>
    <sequence>Randomly allocated by IVRS; stratified by ALT levels at screening and geographic region</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/08/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>240</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Gilead Sciences Inc</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof Paul Desmond</name>
      <address>Department of Gastroenterolgy
St Vincent's Hospital
41 Victoria Parade
Fitzroy VIC 3065</address>
      <phone>+61 3 92883580</phone>
      <fax>+61 3 92883590</fax>
      <email>desmondpv@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof Paul Desmond</name>
      <address>Department of Gastroenterolgy
St Vincent's Hospital
41 Victoria Parade
Fitzroy VIC 3065</address>
      <phone>+61 3 92883580</phone>
      <fax>+61 3 92883590</fax>
      <email>desmondpv@svhm.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>